The complete list of business models in the longevity market
Download our beautiful pitch about the longevity market
In our longevity market deck, you will find everything you need to understand the market
The longevity market is one of the fastest-growing sectors in biotech and consumer health, attracting both venture capital and mainstream attention.
This list covers every major business model currently operating in the longevity market, from consumer supplements to epigenetic reprogramming platforms, and we update it regularly as new models emerge and existing ones evolve.
The models vary widely in how they generate revenue, how defensible they are, and how much capital they require to scale.
And if you want to better understand this new industry, you can download our pitch covering the longevity market.
A quick summary table
| Metric | Value |
|---|---|
| Total business models mapped | 22 |
| Highest scalability score in the longevity market | 9 out of 10 (Supplements Data Upsell, AI Discovery Platform) |
| Models with margin potential of 9 or 10 | 4, all biotech (Epigenetic Reprogramming, AI Discovery, Senolytic, Neuro Longevity) |
| Dominant revenue model | Subscription (consumer) and Licensing (biotech and infrastructure) |
| Capital intensity split | 10 high, 5 medium, 7 low |
| Most common sales motion | DTC content-led (consumer) and Scientific partnering (biotech) |
| Longevity models with defensibility score above 7 | 8 out of 22, concentrated in biotech and infrastructure |
| Best scalability-margin-defensibility balance | Wearables Membership Analytics and Clinical Lab Infrastructure |
| Lowest-ranked longevity business model overall | Cryonics Preservation Services (scalability: 2, margin: 5) |
| Consumer vs. enterprise payer split | Roughly 50% consumer-paid, 50% institutional or pharma-paid |
| Models with fastest path to revenue | Supplements, Telehealth Prescribing, Procedure-Led Clinics |
| Longevity models requiring no clinical trial pathway | Supplements, Wearables, Diagnostics, Concierge Clinics, Cryonics |
In our longevity market deck, we provide the data and the context to understand it
All the business models in the longevity market
Here is a table that maps the main business models in the longevity market, highlighting how they differ in scalability, margins, defensibility, capital intensity, and monetization approach.
| # | Business Model | Description | Example Companies | Scalability | Margin Potential | Defensibility | Capital Intensity | Category | Who Pays | Customer Segment | Revenue Model | Pricing Metric | Sales Motion | Key Strengths | Key Risks | Investor Perspective |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Supplements Data Upsell | Supplements add tests and personalization to increase retention and customer spend | Timeline, Elysium Health, NOVOS, Decode Age, Epiterna | 9 | 8 | 4 | Low | Consumer | Consumers | Health-conscious consumers | Subscription | Per order plus subscription | DTC content-led | Broad TAM and fast monetization | Commoditization and CAC inflation | Great scaler if brand retention becomes durable |
| 2 | AI Discovery Platform Pipeline | AI platform earns partner revenue while advancing internal therapeutic assets | Insilico Medicine, Shift Bioscience, Gero, Deep Longevity | 8 | 9 | 8 | High | Biotech | Pharma partners | Biopharma companies | Licensing | Upfronts plus milestones | Business development | Diversified upside across deals and assets | Platform hype without proof | Huge upside if partnerships validate real engine |
| 3 | Protocolized Lifestyle Platforms | Branded longevity protocols monetize content, products, memberships, and cross-sold services | Blueprint, Decode Age, NOVOS, Elysium Health | 8 | 7 | 6 | Low | Consumer App | Consumers | Early adopters | Subscription | Per member per month | Content-driven DTC | Flexible monetization across audience and products | Founder dependence and fad risk | Attractive if trust institutionalizes beyond personality |
| 4 | Wearables Membership Analytics | Device sales pair with recurring analytics and health recommendations | Oura, Neurable, Liom | 8 | 7 | 7 | High | Hardware | Consumers | Wellness consumers | Per device + subscription | Per device plus subscription | DTC and retail | Habit-forming engagement with recurring data loop | Hardware commoditization and inventory risk | Strong if subscriptions outlive device refresh cycles |
| 5 | Clinical Lab Infrastructure | Sells assays and measurement tools to professional longevity buyers | NADMED, GlycanAge, Generation Lab, Deep Longevity | 8 | 8 | 8 | Medium | Data | Labs and pharma | Labs and clinics | Licensing | Per test or contract | Enterprise sales | Lower CAC with workflow integration | Slow category creation | Best risk-adjusted picks-and-shovels play |
| 6 | Veterinary Longevity Drugs | Develops longevity drugs for pets through veterinary channels | Loyal, Genflow Biosciences, Rejuvenate Bio | 8 | 8 | 7 | High | Biotech | Pet owners | Veterinary networks | Product sales | Per treatment course | Vet-channel sales | Clear willingness to pay and faster proof cycles | Narrower market than human therapeutics | Compelling bridge between longevity story and real treatment |
| 7 | Biological Age Testing | Measures aging biology and monetizes repeat testing plus recommendations | Generation Lab, GlycanAge, Tally Health, Deep Longevity, Viome Life Sciences | 7 | 7 | 6 | Medium | Data | Consumers and clinics | Wellness consumers | Subscription | Per test | DTC and channel partners | Measurement can become category control point | Novelty without actionable outcomes | Attractive if repeat testing becomes behavior |
| 8 | Preventive Diagnostics Membership | Membership bundles recurring tests, interpretation, dashboards, and follow-up recommendations | Function Health, Everlab, Human Longevity, Mito Health | 7 | 7 | 6 | Medium | Services | Consumers and employers | Health-conscious professionals | Subscription | Per member per year | Brand-led DTC | Recurring revenue with cross-sell potential | Weak differentiation and rising CAC | Works if it becomes trusted health platform |
| 9 | Telehealth Longevity Prescribing | Remote clinicians provide prescriptions, labs, and personalized age-optimization protocols | AgelessRx, Everlab, Bionic Health, Mito Health | 7 | 7 | 5 | Low | Services | Consumers | Convenience-seeking consumers | Subscription | Per consult plus refill | Performance marketing | Broad reach with repeatable prescribing revenue | Regulatory shifts and thin evidence | Durable only with strong governance and data |
| 10 | Cell Therapy Automation Infrastructure | Automation tools help therapy developers manufacture complex cell therapies | Cellular Origins, Celularity, Acorn Biolabs | 7 | 7 | 8 | High | Hardware | Biotech companies | Therapy manufacturers | Licensing | Per installed system | Enterprise sales | Exposure to growth without binary trial risk | Long cycles and concentration risk | Strong moat if deployments become standardized products |
| 11 | Biotech Holdings Platforms | Portfolio model owns and incubates multiple longevity assets | Juvenescence, Cambrian Bio, Life Biosciences, Rejuveron Life Sciences | 7 | 5 | 6 | High | Biotech | Investors and partners | Strategic partners | Licensing | NAV and milestones | Capital markets | Diversified exposure across mechanisms and teams | Holding-company discount and sprawl | Bet on allocators, not single programs |
| 12 | Epigenetic Reprogramming Therapeutics | Reprogramming interventions aim to reverse cellular aging states into medicines | NewLimit, Junevity, Retro Biosciences, Turn Biotechnologies, clock.bio | 6 | 10 | 9 | High | Biotech | Investors and partners | Healthcare systems | Licensing | Milestones and partnerships | Fundraising and partnering | Category-defining upside across many indications | Safety, delivery, long timelines | Massive optionality if translational biology holds |
| 13 | Mitochondrial Therapeutics | Targets mitochondrial dysfunction across age-related diseases and chronic decline | Vincere Biosciences, MitoRx Therapeutics, Minovia Therapeutics, Booster Therapeutics, CohBar | 6 | 9 | 7 | High | Biotech | Investors and partners | Healthcare systems | Licensing | Milestones and royalties | Partnering-led | Broad disease relevance with coherent biology | Biomarkers and translation remain difficult | Best where indications have clear readouts |
| 14 | Senolytic Damage-Repair Therapeutics | Removes or repairs accumulated cellular damage causing age-related disease | Arda Therapeutics, Cyclarity Therapeutics, Rubedo Life Sciences, Oisin Biotechnologies, Deciduous Therapeutics | 6 | 9 | 8 | High | Biotech | Investors and partners | Healthcare systems | Licensing | Milestones and partnerships | Scientific partnering | Powerful narrative with broad disease optionality | Mouse biology may not translate | Strong if disease-first and measurable |
| 15 | Neuro Longevity Therapeutics | Applies longevity biology to neurodegeneration and other CNS diseases | SciNeuro Pharmaceuticals, MindImmune Therapeutics, Nura Bio, Jocasta Neuroscience, Alzheon | 6 | 9 | 7 | High | Biotech | Insurers and providers | Healthcare systems | Licensing | Milestones and royalties | Partnering-led | Huge unmet need and blockbuster potential | Binary trials and slow timelines | High upside but punishing development risk |
| 16 | Ophthalmology Device Longevity | Targets age-related eye or neuro degeneration with specialist therapies or devices | Cirrus Therapeutics, Grey Matter Neurosciences, Leucadia Therapeutics, Genflow Biosciences | 6 | 8 | 8 | High | Biotech | Providers and insurers | Specialist providers | Product sales | Per procedure or device | Specialist sales | Clearer endpoints and focused commercial pathways | Technical execution and reimbursement risk | Better entry point than diffuse anti-aging programs |
| 17 | Public Longevity Biopharma | Public-market biotech funds age-related therapeutic pipelines through market access | BioAge Labs, Celularity, Unity Biotechnology, CohBar, Genflow Biosciences | 6 | 5 | 5 | High | Biotech | Public investors | Public markets | Licensing | Milestone-driven valuation | Investor relations | Financing flexibility and public visibility | Volatility and dilution pressure | Underwrite runway and milestone quality first |
| 18 | Regenerative Product Hybrid | Current regenerative products support a longer-term advanced therapy pipeline | Celularity, Minovia Therapeutics, Genflow Biosciences, Rejuvenate Bio | 5 | 6 | 7 | High | Biotech | Providers and partners | Hospitals and partners | Product sales | Per product plus milestones | Hybrid commercial BD | Current revenue can offset pipeline risk | Strategic sprawl and mixed identity | Valuable only if hybrid creates genuine leverage |
| 19 | Concierge Longevity Clinics | High-touch clinics sell premium memberships and white-glove personalized care | Fountain Life, Biograph, Bionic Health, Neko Health | 5 | 7 | 6 | High | Services | Affluent consumers | UHNW individuals | Subscription | Per member per year | Referral-led sales | Premium pricing with low reimbursement exposure | Narrow TAM and physician bottlenecks | Good business, rarely true tech multiple |
| 20 | Procedure-Led Longevity Clinics | Specific cash-pay procedures drive clinic economics and repeat visits | Circulate Health, Fountain Life, Biograph | 4 | 6 | 4 | High | Services | Consumers | Affluent biohackers | Transaction fee | Per procedure | Local trust-led sales | Immediate revenue with clear willingness to pay | Scientific scrutiny and weak moat | Treat as clinic chain, not breakthrough platform |
| 21 | Research-Lab Longevity Platforms | Large internal research labs pursue foundational science before commercialization | Altos Labs, Calico Life Sciences, Retro Biosciences, NewLimit | 3 | 2 | 9 | High | Biotech | Founders and investors | Research organizations | Licensing | None pre-commercial | Scientific prestige | Elite talent and deep scientific optionality | Indefinite timelines and weak commercialization | Value depends on translation into licensable assets |
| 22 | Cryonics Preservation Services | Customers prepay for preservation and long-term storage of biological material | Tomorrow Bio, Acorn Biolabs | 2 | 5 | 6 | High | Services | Consumers and families | Affluent futurists | Subscription | Per contract | Community-driven education | Deep commitment and limited direct competition | Tiny TAM and extreme trust burden | Trust business with unusual duration risk |
In our longevity market deck, we will give you useful market maps and grids
Key insights about business models in the longevity market
Insights
- Every longevity business model with a margin potential of 9 or 10 is biotech, but all of them also carry high capital intensity, creating a direct tradeoff: the best economics on paper come with the heaviest financing burden.
- Wearables are one of the few longevity models that score well across scalability, margins, and defensibility at the same time, making hardware-plus-subscription one of the cleanest compounder profiles in the whole longevity market.
- Consumer longevity models account for roughly half of all revenue pools in this market, but only two consumer-led models score 7 or higher on defensibility, meaning most near-term longevity revenue sits in structurally fragile businesses.
- Clinical measurement infrastructure, like longevity assays and lab tools sold to professional buyers, scores better than most end-consumer longevity brands because it avoids heavy consumer acquisition costs and embeds directly into professional workflows.
- Veterinary longevity drugs combine biotech-style defensibility with faster feedback loops and clearer buyer willingness to pay than almost any human therapeutic program in the longevity market.
- Research-lab longevity platforms like Altos Labs and Calico score near the top for defensibility but near the bottom commercially, confirming that elite science does not automatically translate into a productizable longevity business.
- Biological age testing and preventive diagnostics membership models score almost identically, which suggests that measurement alone is not a durable advantage in the longevity market; long-term value depends on converting episodic testing into ongoing behavior or platform control.
In our longevity market deck, we identify repeatable patterns you can use if you’re building in this market
A few words about our methodology
This table maps the main business models used by startups in the longevity market.
To build it, we first analyzed the leading longevity startups and examined how they actually generate revenue.
We then grouped similar approaches into clear business model categories. The goal was to capture meaningful differences without creating an overwhelming number of models.
Each longevity business model is evaluated across four structural dimensions: scalability, margin potential, defensibility, and capital intensity.
Scalability measures how easily the model can grow without proportional increases in cost. Margin potential reflects the long-term gross margin typically achievable once the model reaches maturity.
Defensibility captures how sustainable the competitive advantage can be over time, considering factors like switching costs, network effects, or proprietary data.
Capital intensity indicates how much upfront investment is usually required to build and scale the model.
For scalability, margin potential, and defensibility, scores range from 0 to 10. Lower scores indicate structural limitations, while scores above 7 generally signal strong economic potential.
These scores are not precise forecasts. They reflect the typical economics we observe across longevity companies using that model.
This framework is part of the broader research behind our report covering the longevity market, where we analyze the ecosystem in much more detail.
If you want to better understand the ecosystem, you can also check our ranking of startups with the most fundraising in the longevity market and the list of the startups with the biggest valuations in the longevity market.
If you want more detail about our business model analysis or about a specific longevity company, feel free to contact us. We will gladly explain.
In our longevity market deck, we identify repeatable patterns you can use if you’re building in this market
Related blog posts
- The most recent news in the longevity market
- The most recent funding news in the longevity market
- The latest developments shaping the longevity market
- The evolution of funding activity in the longevity market
